Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Elanco Animal Health turns veterinary science into revenue isn鈥檛 easy鈥攅ach 10-K details dozens of R&D pipeline assets, FDA approvals, and integration costs from the Bayer Animal Health acquisition. If you have ever asked, 鈥淲here can I read Elanco鈥檚 quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I locate Elanco insider trading Form 4 transactions?鈥� you already know the challenge.
Stock Titan solves it. Our AI-powered summaries translate the technical language in every Elanco SEC document into plain English, flagging segment margins, companion-animal growth, and farm-animal productivity trends. Receive real-time alerts the moment an Elanco Form 4 insider transactions real-time filing hits EDGAR, or open an Elanco 8-K material events explained card to see if a new parasiticide received FDA approval鈥攁ll without wading through hundreds of pages.
Here鈥檚 what you can explore in seconds:
- Elanco annual report 10-K simplified鈥擜I highlights pipeline updates, manufacturing efficiencies, and acquisition synergies.
- Elanco quarterly earnings report 10-Q filing鈥攃ompare sequential companion-animal sales and R&D spend.
- Elanco proxy statement executive compensation鈥攕ee how leadership incentives align with product launch milestones.
- Elanco executive stock transactions Form 4鈥攎onitor insider buying ahead of material announcements.
Whether you search 鈥渦nderstanding Elanco SEC documents with AI鈥� or need fast Elanco earnings report filing analysis, our platform keeps every filing type in one place, updated the moment Elanco submits it. Save hours, spot trends early, and make better calls on ELAN.
Form 8-K Highlights: Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) filed a current report covering two principal matters: (1) departure of its Chief Operating Officer and (2) a corporate name and ticker change.
Executive departure (Item 5.02): Effective July 1, 2025, COO Bren Kern鈥檚 employment terminated in connection with a previously announced reduction-in-force. Under a Separation and Release Agreement, he will receive 12 months of base salary and up to 12 months of continued health-care benefits, conditioned upon standard release and covenant provisions. The agreement is attached as Exhibit 10.1.
Name and ticker change (Item 5.03): A Certificate of Amendment filed June 30, 2025, changed the company鈥檚 legal name from Eyenovia, Inc. to Hyperion DeFi, Inc., effective 8:00 a.m. ET on July 1, 2025. Board approval under Delaware General Corporation Law 搂242 was sufficient; no stockholder vote was required. Common shares retain the same rights and CUSIP, but the Nasdaq ticker will convert from 鈥淓YEN鈥� to 鈥淗YPD鈥� beginning July 3, 2025.
Reg FD disclosure (Item 7.01): A press release regarding the rebrand and ticker change was furnished (Exhibit 99.1) and is not deemed 鈥渇iled鈥� for Exchange Act liability.
Exhibits:
- 3.1 鈥� Certificate of Amendment (Name Change)
- 10.1 鈥� Separation and Release Agreement (COO)
- 99.1 鈥� Press Release announcing changes
- 104 鈥� Inline XBRL cover page
The filing is primarily administrative; it signals a strategic rebranding without altering share structure, while simultaneously disclosing senior management turnover that may raise continuity concerns.
On 27 June 2025, Elanco Animal Health Inc. (ELAN) disclosed in a Form 4 that Executive Vice President of U.S. Pet Health & Global Digital Transformation Rajeev A. Modi received 98.9937 deferred stock units (DSUs) at a reference price of $14.29 under the company鈥檚 Executive Deferral and Stock Match Plan. Each DSU converts into one common share or its cash equivalent upon settlement after employment ends or in a predetermined future year. The award is classified as transaction code 鈥淎,鈥� meaning it is a compensation grant rather than an open-market purchase. Modi now directly holds 6,460.6903 DSUs; no shares were sold or otherwise disposed. The grant is small鈥攚orth roughly $1.4 thousand鈥攁nd does not materially alter insider ownership or the company鈥檚 share count, but it marginally reinforces management-shareholder alignment.
Elanco Animal Health Inc. (ELAN) 鈥� Form 4 insider filing
On 27 June 2025, President & CEO Jeffrey N. Simmons acquired 193.7887 deferred stock units (DSUs) under the company鈥檚 Executive Deferral and Stock Match Plan at a reference price of $14.29. Each DSU represents the right to receive either one common share or a cash equivalent upon settlement, which occurs after employment ends or in a pre-elected future year. Following the transaction, Simmons now beneficially owns 16,849.4516 DSUs, held directly.
The filing discloses no open-market purchases or sales; the units were issued as part of a compensation-related deferral program. The size of the award鈥攚orth roughly US$2.8 thousand based on the reference price鈥攊s immaterial relative to Elanco鈥檚 market capitalisation and Simmons鈥� existing holdings, but it does incrementally increase insider ownership.
Elanco Animal Health (NYSE:ELAN) filed an 8-K reporting a First Amendment to its Receivables Loan Agreement with Rabobank. The amendment extends the accounts-receivable securitization facility鈥檚 maturity from Aug 3 2026 to Jun 26 2028, keeps Elanco as performance guarantor, Elanco SPEAR LLC as borrower, and Elanco US as servicer.
The filing is deemed a material definitive agreement (Item 1.01) and a direct financial obligation/off-balance-sheet arrangement (Item 2.03). Financial amounts were not disclosed, but the longer tenor is expected to improve liquidity and refinancing flexibility. Investors should review Exhibit 10.1 for precise covenant changes.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
What is the core mission of Elanco Animal Health?
Which business segments does Elanco operate in?
How does Elanco generate revenue?
What distinguishes Elanco from other companies in the animal health industry?
How does Elanco ensure the quality and safety of its products?
What role do strategic acquisitions play in Elanco鈥檚 business model?
In which regions does Elanco operate?
How does Elanco contribute to food safety?
